Monoclonal antibody combo authorized to prevent COVID-19 in certain patients
The Food and Drug Administration last week authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to prevent COVID-19 in certain children and adults exposed to SARS-CoV-2 who are not fully vaccinated against COVID-19 and at high-risk for progressing to severe disease.
The combination therapy is currently authorized for use only in states and territories having 5% or fewer variants resistant to bamlanivimab and etesevimab administered together.
FDA last month authorized using the monoclonal antibody therapy REGEN-COV to prevent COVID-19 in such patients.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…